ArticleBMC public health2021
Sarcopenia screening strategies in older people: a cost effectiveness analysis in Iran.
Article in BMC public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Muscle elasticity variations in assessing age-related changes in adults - A systematic review.Geriatrics & gerontology international · 2025Pooled it
- Prevalence of, and factors associated with, sarcopenia in Iran: a systematic review and meta-analysis.Frontiers in nutrition · 2024Pooled it
- Consensus recommendations on age-related sarcopenia in South Asia: A nutrition-focused approach.Osteoporosis and sarcopenia · 2026Review
- An exploratory multi-biomarker panel including fecal calprotectin, Brain-Derived Neurotrophic Factor, Fibroblast-Growth Factor-21 and irisin shows poor diagnostic accuracy for detecting probable sarcopenia in community-dwelling older persons.Aging clinical and experimental research · 2026Article
- Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Musculoskeletal Disorders.Acta medica Philippina · 2026Article
- Health economics evaluation of screening for sarcopenia among community-dwelling older persons.BMC public health · 2025Article
- Assessment of SARC-F Sensitivity for Probable Sarcopenia Among Community-Dwelling Older Adults: Cross-Sectional Questionnaire Study.JMIRx med · 2025Article
- Prevalence and factors associated with sarcopenia in elderly people referred by Primary Healthcare to a specialized service in an area of the Federal District of Brazil, 2015-2017.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025Article
- Article
- Perceptions of healthcare providers on benefits, risks and barriers regarding intradialytic exercise among haemodialysis patients.International journal of qualitative studies on health and well-being · 2024Article
- Diagnostic accuracy analysis of SARC-F, its modified versions and the Quality of Life in Sarcopenia questionnaire in screening for sarcopenia in nursing home residents.Geriatrics & gerontology international · 2024Article
- Sarcopenia in the Oldest-Old Adults in the Capital of Brazil: Prevalence and Its Associated Risk Factors.Nutrients · 2024Article
- Economic burden of sarcopenia-related disability in the elderly population: a study in Iran.BMC research notes · 2024Article
- Comparison of the performance of four screening tools for sarcopenia in patients with chronic liver disease.International journal of nursing sciences · 2024Article
- Cost-effectiveness analysis of sarcopenia management interventions in Iran.BMC public health · 2023Article
- Editorial: Community series - reducing the burden of age-related disease in relation to osteoporosis, sarcopenia and osteosarcopenia, volume II.Frontiers in medicine · 2023Article
- Ethical considerations in sarcopenia research.Journal of medical ethics and history of medicine · 2023Article
- Oculomics for sarcopenia prediction: a machine learning approach toward predictive, preventive, and personalized medicine.The EPMA journal · 2022Article
- Self-reported difficulty in walking 400 meters: the "red flag" for probable sarcopenia.BMC geriatrics · 2022Article
- South Asian Working Action Group on SARCOpenia (SWAG-SARCO) - A consensus document.Osteoporosis and sarcopenia · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSarcopenia is an important age-related disease which can lead to an increased risk of mortality, falls, fractures, and poor quality of life. So, timely detection can be effective in reducing the burden of disease. The aim of this study was to identify the most cost-effective strategy for sarcopenia screening in Iran. MATERIALS AND
methodsWe constructed a Markov transition model over a life-time horizon based on natural history. Compared strategies included Sarcopenia scoring assessment models (SarSA-Mod), European working group on sarcopenia in older people (EWGSOP), Mini sarcopenia risk assessment (MSRA) and SARC-F. Parameters values were extracted from primary data and the literature, and the costs and Quality-adjusted life years (QALYs) were calculated for each strategy. Sensitivity analysis of uncertain parameters was also performed to determine the robustness of the model. Analysis was performed using 2020 version of TreeAge Pro software.
resultsAll four screening strategies increased life time QALYs. After removing dominated strategy, the incremental cost per QALY gained for sarcopenia screening varied from $1875.67 for EWGSOP to $1898.33 for MSRA. Our base-case analysis showed that the most cost-effective strategy was EWGSOP and 2nd best was SarSA-Mod with $43,414.3 and $42,663.3 net monetary benefits given one GDP per capita ($5520.311) as willingness to pay, respectively. Sensitivity analysis of model parameters also showed robustness of results.
conclusionsThe results of the study, as the first economic evaluation of sarcopenia screening, showed that the EWGSOP strategy is more cost-effective than other strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.